CELGENE CORP Contracts & Agreements

104 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Assignment, Assumption and Amendment Agreement, dated as of November 20, 2019, among Bristol-Myers Squibb Company, Celgene Corporation, American Stock Transfer & Trust Company,...
Stock Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
Asset Purchase Agreement dated August 25, 2019, by and between Celgene Corporation, as seller, and Amgen Inc., as purchaser
Purchase Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated October 7, 2010 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated August 9, 2012 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated August 6, 2013 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated May 15, 2014 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated August 12, 2015 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated August 10, 2017 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated November 9, 2017 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust Company,...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
First Supplemental Indenture, dated May 1, 2019, to Indenture, dated February 20, 2018 by and between Celgene Corporation, as Issuer, and The Bank of New York Mellon Trust...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2019
Form of Contingent Value Rights Agreement by and between Bristol-Myers Squibb Company and [Trustee]
CELGENE CORP
Pharmaceuticals
NY
2019
Celgene Corporation Executive Severance Plan
Severance Agreements
CELGENE CORP
Pharmaceuticals
DE
2019
Agreement and Plan of Merger by and among Bristol-Myers Squibb Company, Burgundy Merger Sub, Inc. and Celgene Corporation, dated as of January 2, 2019
Merger Agreements
CELGENE CORP
Pharmaceuticals
DE
2019
Offer Letter
CELGENE CORP
Pharmaceuticals
2018
Offer Letter
CELGENE CORP
2018
Amended and Restated Credit Agreement, dated as of April 25, 2018
Credit Agreements
CELGENE CORP
2018
Indenture, dated as of February 20, 2018, relating to the 2.875% Senior Notes due 2021, the 3.250% Senior Notes due 2023, the 3.900% Senior Notes due 2028 and the 4.550% Senior...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2018
Form of 2.875% Senior Note due 2021
Note Agreements
CELGENE CORP
2018
Form of 3.250% Senior Note due 2023
Note Agreements
CELGENE CORP
2018
Form of 3.900% Senior Note due 2028
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2018
Form of 4.550% Senior Note due 2048
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2018
Agreement and Plan of Merger, dated as of January 21, 2018, among Celgene Corporation, Blue Magpie Corporation and Juno Therapeutics, Inc
Merger Agreements
CELGENE CORP
2018
Form of 2.750% Senior Note due 2023
Note Agreements
CELGENE CORP
2017
Form of 3.450% Senior Note due 2027
Note Agreements
CELGENE CORP
2017
Form of 4.350% Senior Note due 2047
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2017
Underwriting Agreement, dated as of October 31, 2017, among the Company and Barclays Capital Inc., Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC, J.P. Morgan...
Underwriting Agreements
CELGENE CORP
Pharmaceuticals
NY
2017
CelgeneCorporation 2017Stock Incentive Plan (Amendedand Restated as of April 19, 2017) Article 1. PURPOSE
Bonus & Incentive Agreements
CELGENE CORP
2017
SIGNATURE PAGE
CELGENE CORP
2017
CELGENE CORPORATION STOCK OPTION AGREEMENT PURSUANT TO THE 2008 STOCK INCENTIVE PLAN (Amended & Restated as of April 15, 2015) (As Further Amended as of June 15, 2016)
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
2017
RESTRICTED STOCK UNIT AGREEMENT PURSUANT TO THE CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (Amended & Restated as of April 15, 2015) (As Further Amended as of June 15, 2016)...
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
2017
PERFORMANCE STOCK UNIT AGREEMENT PURSUANT TO THE CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (Amended and Restated as of April 15, 2015) (Amended & Restated as of June 15, 2016)
Bonus & Incentive Agreements
CELGENE CORP
2017
AMENDMENT TO THE CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF APRIL 15, 2015)
Bonus & Incentive Agreements
CELGENE CORP
2016
[Remainder of page intentionally left blank]
CELGENE CORP
Pharmaceuticals
NY
2016
AMENDMENT NO. 3 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreements
CELGENE CORP
Pharmaceuticals
2016
AMENDMENT NO. 4 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreements
CELGENE CORP
2016
JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, NY 10179
CELGENE CORP
Pharmaceuticals
2015
CELGENE CORPORATION, as Issuer, and TheBank of New York Mellon Trust Company, N.A., as Trustee INDENTURE Dated as of August 12, 2015
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2015
Form of 2.125% Senior Note due 2018 GLOBAL SECURITY
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2015
Form of 2.875% Senior Note due 2020 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2015
Form of 3.550% Senior Note due 2022 GLOBAL SECURITY
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2015
Form of 3.875% Senior Note due 2025 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2015
Form of 5.000% Senior Note due 2045 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2015
Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) Article 1. PURPOSE
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
DE
2015
AGREEMENT AND PLAN OF MERGER by and among CELGENE CORPORATION, STRIX CORPORATION and RECEPTOS, INC. Dated as of July 14, 2015
Merger Agreements
CELGENE CORP
2015
JPMorganChase Bank, N.A. J.P.Morgan Securities LLC 383 Madison Avenue New York, NY 10179
CELGENE CORP
Pharmaceuticals
NY
2015
Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) Article 1. PURPOSE
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
DE
2015
U.S. $1,750,000,000 SECOND AMENDED AND RESTATED CREDIT AGREEMENT Dated as of April 17, 2015 Among CELGENE CORPORATION as Borrower and THE INITIAL LENDERS NAMED HEREIN as Initial...
Credit Agreements
CELGENE CORP
2015
LICENSE AGREEMENT
License Agreements
CELGENE CORP
Pharmaceuticals
NY
2014
AMENDMENT No. 1 To CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF APRIL 17, 2013)
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
2014
CELGENECORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of May 15, 2014
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2014
Form of 2.250% Senior Note due 2019 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2014
Form of 3.625% Senior Note due 2024 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2014
Form of 4.625% Senior Note due 2044 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2014
CELGENE CORPORATION $500,000,000 2.250% SENIOR NOTES DUE 2019 $1,000,000,000 3.625% SENIOR NOTES DUE 2024 $1,000,000,000 4.625% SENIOR NOTES DUE 2044 UNDERWRITING AGREEMENT May 6,...
Underwriting Agreements
CELGENE CORP
2014
CELGENE CORPORATION, as Issuer, and THE BANK OFNEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of August 6, 2013 CROSS-REFERENCE TABLE
Indenture Agreements
CELGENE CORP
2013
Form of 2.300% Senior Note due 2018 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2013
Form of 4.000% Senior Note due 2023 GLOBAL SECURITY
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2013
Form of 5.250% Senior Note due 2043 GLOBAL SECURITY
Note Agreements
CELGENE CORP
2013
CELGENE CORPORATION $400,000,000 2.300% SENIOR NOTES DUE 2018 $700,000,000 4.000% SENIOR NOTES DUE 2023 $400,000,000 5.250% SENIOR NOTES DUE 2043 UNDERWRITING AGREEMENT August 1,...
Underwriting Agreements
CELGENE CORP
Pharmaceuticals
NY
2013
CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF APRIL 17, 2013) Article 1. PURPOSE
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
DE
2013
U.S. $1,500,000,000 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of April 18, 2013 Among CELGENE CORPORATION as Borrower and THE INITIAL LENDERS NAMED HEREIN as Initial Lenders...
Credit Agreements
CELGENE CORP
2013
CELGENE CORPORATION STOCK OPTION AGREEMENT PURSUANT TO THE 2008 STOCK INCENTIVE PLAN (Amended and Restated as of June 17, 2009)
Bonus & Incentive Agreements
CELGENE CORP
2013
RESTRICTED STOCK UNIT AGREEMENT PURSUANT TO THE CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (Amended & Restated as of June 17, 2009) (for US employees)
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
2013
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of August 9, 2012 CROSS-REFERENCE TABLE
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2012
Form of 1.900% Senior Note due 2017 GLOBAL SECURITY
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2012
Form of 3.250% Senior Note due 2022 GLOBAL SECURITY
Note Agreements
CELGENE CORP
Pharmaceuticals
NY
2012
CELGENE CORPORATION $500,000,000 1.900% SENIOR NOTES DUE 2017 $1,000,000,000 3.250% SENIOR NOTES DUE 2022 UNDERWRITING AGREEMENT August 6, 2012 August 6, 2012
Underwriting Agreements
CELGENE CORP
Pharmaceuticals
NY
2012
AMENDMENT NO. 2 TO THE CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF JUNE 17, 2009)
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
2012
U.S. $1,000,000,000 CREDIT AGREEMENT Dated as of September 2, 2011 Among CELGENE CORPORATION as Borrower and THE INITIAL LENDERS NAMED HEREIN as Initial Lenders and CITIBANK, N.A....
Credit Agreements
CELGENE CORP
Pharmaceuticals
DE
2011
AMENDMENT NO. 1 TO THE CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF JUNE 17, 2009)
Bonus & Incentive Agreements
CELGENE CORP
2011
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Datedas of October 7, 2010
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2010
CELGENE CORPORATION
CELGENE CORP
2010
CELGENE CORPORATION
CELGENE CORP
2010
CELGENE CORPORATION
CELGENE CORP
Pharmaceuticals
NY
2010
CELGENE CORPORATION
CELGENE CORP
2010
AGREEMENT AND PLAN OF MERGER DATED AS OF JUNE 30, 2010 AMONG CELGENE CORPORATION, ARTISTRY ACQUISITION CORP. AND ABRAXIS BIOSCIENCE, INC.
Merger Agreements
CELGENE CORP
2010
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between CELGENE CORPORATION and [TRUSTEE] Dated as of [], 2010
CELGENE CORP
Pharmaceuticals
NY
2010
VOTING AGREEMENT
Voting Agreements
CELGENE CORP
Pharmaceuticals
DE
2010
NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY AGREEMENT
Non-Competition Agreements
CELGENE CORP
2010
STOCKHOLDERS AGREEMENT
CELGENE CORP
Pharmaceuticals
DE
2010
AMENDMENT NO. 2 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreements
CELGENE CORP
2010
SERVICES AGREEMENT
Services Agreements
CELGENE CORP
Pharmaceuticals
NJ
2010
AMENDMENT NO. 2 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreements
CELGENE CORP
2010
Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of June 17, 2009) Article 1. PURPOSE
Bonus & Incentive Agreements
CELGENE CORP
Pharmaceuticals
DE
2009
In August 2000, we acquired Signal Pharmaceuticals, Inc., currently Signal Pharmaceuticals, LLC, d/b/a Celgene Research San Diego, a privately held biopharmaceutical company...
Development Agreements
CELGENE CORP
Pharmaceuticals
2009
In August 2000, we acquired Signal Pharmaceuticals, Inc., currently Signal Pharmaceuticals, LLC, d/b/a Celgene Research San Diego, a privately held biopharmaceutical company...
Development Agreements
CELGENE CORP
Pharmaceuticals
2009
In August 2000, we acquired Signal Pharmaceuticals, Inc., currently Signal Pharmaceuticals, LLC, d/b/a Celgene Research San Diego, a privately held biopharmaceutical company...
Development Agreements
CELGENE CORP
2009
In August 2000, we acquired Signal Pharmaceuticals, Inc., currently Signal Pharmaceuticals, LLC, d/b/a Celgene Research San Diego, a privately held biopharmaceutical company...
Development Agreements
CELGENE CORP
Pharmaceuticals
2009
Three-Month Periods Ended
CELGENE CORP
2008
Celgene Corporation 2008 Stock Incentive Plan Article 1. PURPOSE
Bonus & Incentive Agreements
CELGENE CORP
2008
Three-Month Periods Ended
CELGENE CORP
2008
Three-Month Periods Ended
CELGENE CORP
Pharmaceuticals
2008
Three-Month Periods Ended
CELGENE CORP
Pharmaceuticals
2008
Three-Month Periods Ended
CELGENE CORP
2008
Three-Month Periods Ended
CELGENE CORP
2008
AGREEMENT AND PLAN OF MERGER by and among CELGENE CORPORATION, COBALT ACQUISITION LLC and PHARMION CORPORATION November 18, 2007
Merger Agreements
CELGENE CORP
2007
VOTING AGREEMENT
Voting Agreements
CELGENE CORP
Pharmaceuticals
2007
Three-Month Periods Ended
CELGENE CORP
Pharmaceuticals
2007
Three-Month Periods Ended
CELGENE CORP
2007
Three-Month Period Ended
CELGENE CORP
2007
Underwriting Agreement, dated as of February 8, 2018, among the Company and Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill...
Underwriting Agreements
CELGENE CORP
Pharmaceuticals
NY
2018
Indenture, dated as of November 9, 2017, relating to the 2.750% Senior Notes due 2023, the 3.450% Senior Notes due 2027 and the 4.350% Senior Notes due 2047 between the Company...
Indenture Agreements
CELGENE CORP
Pharmaceuticals
NY
2017
Fiscal Quarter EndingMaximum RatioSeptember 30, 20155.25:1.00December 31, 2015 to March 31, 20164.95:1.00June 30, 2016 to September 30, 20164.25:1.00December 31, 2016 to March 31,...
CELGENE CORP
Pharmaceuticals
NY
2016
CELGENE CORPORATION $1,000,000,000 2.125% SENIOR NOTESDUE 2018 $1,500,000,000 2.875% SENIOR NOTESDUE 2020 $1,000,000,000 3.550% SENIOR NOTESDUE 2022 $2,500,000,000 3.875% SENIOR...
Underwriting Agreements
CELGENE CORP
Pharmaceuticals
NY
2015